Evaluation of the Immature Platelet Fraction (IPF) Parameter on the Sysmex® XE-2100 Automated Hematology Analyzer in Predicting Platelet Recovery in Patients with Chemotherapy Induced Thrombocytopenia
12:00 PM to 1:00PM (Americas) Central Time (US & Canada)
Dr. Cheryl Hirsch-Ginsberg, Professor, Department of Pathology/Laboratory Medicine, Division of Pathology/Lab Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Thrombocytopenia is a common side effect of chemotherapy. Apart from monitoring the platelet count, bone marrow aspirates quantifying the number and morphology of megakaryocytes have been used to determine if there is a recovery of effective thrombopoiesis, especially with intensive therapy. Alternatively, the ability to quantify the least mature platelets provides a minimally invasive measure of thrombopoietic activity of the bone marrow. This can be accomplished in the high volume hematology or core laboratory using the Immature Platelet Fraction (IPF) parameter of the Sysmex XE2100 Automated Hematology Analyzer. The purpose of this study was to determine the relationship of the platelet count to the IPF in patients immediately following successive courses of myelosuppressive chemotherapy.
Review current and new methods used to determine if there is a recovery of effective thrombopoiesis in patients receiving chemotherapy.
Explain the relationship of the platelet count to the IPF in patients immediately following myelosuppresssive chemotherapy.
Describe additional ongoing studies to determine the role of IPF in predicting time to platelet recovery.